Free tool
FAERS Monitor: Lastacaft
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022134 or its brand name (Lastacaft, Alcaftadine). Reports on generic versions are filed under their own applications.
Reports
907
Serious
133
15% of reports
Hospitalization
37
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ocular hyperaemia299
- eye irritation171
- eye pain103
- eye pruritus103
- eye swelling84
- drug ineffective65
- hypersensitivity64
- lacrimation increased57
- eye discharge47
- eyelid oedema42
- erythema of eyelid39
- conjunctivitis38
- vision blurred37
- headache36
- off label use36
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 60 |
| 2012 | 138 |
| 2013 | 66 |
| 2014 | 163 |
| 2015 | 83 |
| 2016 | 49 |
| 2017 | 18 |
| 2018 | 19 |
| 2019 | 30 |
| 2020 | 19 |
| 2021 | 17 |
| 2022 | 21 |
| 2023 | 104 |
| 2024 | 67 |
| 2025 | 37 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| erythema of eyelidSignal | 39 | 168.2 | 123.6 | 6,273 |
| ocular hyperaemiaSignal | 299 | 147.0 | 133.9 | 43,042 |
| eye dischargeSignal | 47 | 105.4 | 79.7 | 4,736 |
| eyelid oedemaSignal | 42 | 84.1 | 62.5 | 3,355 |
| eye pruritusSignal | 103 | 71.3 | 59.4 | 7,059 |
| eye irritationSignal | 171 | 69.1 | 60.4 | 11,405 |
| eye swellingSignal | 84 | 52.5 | 42.8 | 4,188 |
| conjunctivitisSignal | 38 | 47.6 | 34.9 | 1,685 |
| lacrimation increasedSignal | 57 | 43.8 | 34.1 | 2,342 |
| eye painSignal | 103 | 42.4 | 35.4 | 4,127 |
| hypersensitivitySignal | 64 | 8.0 | 6.3 | 388 |
| vision blurredSignal | 37 | 6.3 | 4.6 | 159 |
| headache | 36 | 1.3 | 1.0 | 3 |
| drug ineffective | 65 | 1.1 | 0.9 | 1 |
| off label use | 36 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.